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The Epstein-Barr virus (EBV) has been detected in subsets of breast cancers. In order to elaborate on these
observations, we quantified by real-time PCR (Q-PCR) the EBV genome in biopsy specimens of breast cancer
tissue as well as in tumor cells isolated by microdissection. Our findings show that EBV genomes can be
detected by Q-PCR in about half of tumor specimens, usually in low copy numbers. However, we also found that
the viral load is highly variable from tumor to tumor. Moreover, EBV genomes are heterogeneously distributed
in morphologically identical tumor cells, with some clusters of isolated tumor cells containing relatively high
genome numbers while other tumor cells isolated from the same specimen may be negative for EBV DNA. Using
reverse transcription-PCR, we detected EBV gene transcripts: EBNA-1 in almost all of the EBV-positive tumors
and RNA of the EBV oncoprotein LMP-1 in a smaller subset of the tissues analyzed. Moreover, BARF-1 RNA
was detected in half of the cases studied. Furthermore, we observed that in vitro EBV infection of breast
carcinoma cells confers resistance to paclitaxel (taxol) and provokes overexpression of a multidrug resistance
gene (MDR1). Consequently, even if a small number of breast cancer cells are EBV infected, the impact of EBV
infection on the efficiency of anticancer treatment might be of importance.
The Epstein-Barr virus (EBV), a ubiquitous human herpesvi-
rus, is associated with the development of different epithelial
malignancies (28), including nasopharyngeal carcinoma (NPC). It
has also been linked with subsets of other types of carcinomas,
including gastric carcinoma and lymphoepithelioma-like carci-
noma in salivary glands and thymus (32, 44). Several laboratories
have reported detection of EBV in a subset of breast tumors (3,
10, 19, 23). However, negative results have also been reported (6,
9, 14, 27). Nevertheless, in most of the studies, a low viral load was
detected in breast cancer biopsy specimens but the infected cells
were not clearly identified. In the study presented here, we used
real-time PCR (Q-PCR) to quantify the copy numbers of the
EBV genome in biopsy specimens as well as in microdissected
tumor cells. The results show that breast cancer cells harbor the
viral genome. However, through microdissection and isolation of
pure tumor cells, we now find that even in EBV-positive tumor
samples, many tumor cells do not contain EBV genomes and that
the breast carcinomas are highly heterogeneous in terms of ge-
nome content and distribution. Moreover, using reverse tran-
scription-PCR (RT-PCR), we detected EBNA-1 and BARF-1
transcripts in almost all of the EBV-positive tumors and LMP-1
RNA in 3 of the 15 cases studied. The findings raise the possibility
that although EBV is unlikely to have an etiologic role in the
genesis of breast cancer, the virus might contribute to tumor
progression. Finally, the potential impact of EBV in breast cancer
progression was evaluated by estimation of resistance to chemo-
therapeutic agents on in vitro-infected MDA-MB-231 cells. The
results show that EBV confers paclitaxel (taxol) resistance and
causes overexpression of a multidrug resistance gene (MDR1).
Consequently, if even a small number of breast cancer cells are
EBV infected, the impact of EBV infection on the efficiency of
anticancer treatment might be of importance.
MATERIALS AND METHODS
Biopsy specimens. This study includes breast cancer specimens from 37 pa-
tients from Institut Gustave Roussy (Villejuif, France) and 95 from the Centre
Oscar Lambret (Lille, France). Tumor specimens were obtained with the agree-
ment of the patients and were solely adenocarcinomas. At the time of collection,
fat was removed and samples were divided into three parts. The first part was
submitted for histological study and histoprognostic grading according to the
method of Contesso et al. (8). The second part of the sample was immediately
frozen in liquid nitrogen for estrogen receptor (ER) and progesterone receptor
(PR) assays (2). The third part was used in molecular biologic assays (30).
The median age of the patients was 58 years (range, 26 to 90 years). Node
involvement was detected in 58.3% of the cases. The tumor size was 1 cm in
diameter in 2.3% of the cases, 1 and 3 cm in 58.6% of cases, and 3 cm in
39.1% of cases. The tumor type was ductal in 58.6% of the cases, lobular
in 11.5% of the cases, and of other types in 29.8% of the cases. The distribution
of histoprognostic grading was 8.4% for type I, 41% for type II, and 50.6% for
type III (8); 66% of the tumors were ER positive, and 64% were PR positive.
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Control DNA from two biopsy specimens of nasopharyngeal carcinoma and
five pellets of peripheral blood cells was taken from the study described by
Grunewald et al. (12).
Laser capture microdissection. Six frozen breast cancer biopsy specimens col-
lected at Institut Gustave Roussy were taken for microdissection. In each case,
one tissue block of breast tumor was cut on a cryostat microtome into 10-m
sections. These were mounted on uncoated slides and fixed immediately in 70%
ethanol for 30 s, stained with Mayer’s hematoxylin, and then washed in 70%,
90%, and 95% ethanol for 30 s each. Staining was followed by two 60-s dehy-
dration steps in xylene before the samples were air dried. The sections were then
microdissected in order to select the tumor cell component. Four samples were
dissected with the PixCell II laser capture microdissection (LCM) Arcturus
system (Mountain View, California), and two samples were dissected with a
Laser Leica LMD. For each tumor block, three or more separate microdissec-
tions were taken from different anatomic areas but with no discernible difference
in lymphocytic infiltration, cell density, and stromal composition. A minimum of
5,000 cells was captured. The number of cells was evaluated according to the
manufacturers’ instructions: the number of pulses (Arcturus) or the measure-
ment of the cell surface areas (Leica). Cell populations were estimated to be
homogeneous by microscopic visualization. DNA was extracted and subsequently
used for Q-PCR.
DNA preparation and Q-PCR. DNA from pulverized frozen specimens or
microdissected cells was extracted with a QIAMP mini kit (QIAGEN, Courta-
boeuf, France) according to the manufacturer’s instructions. Q-PCR of the EBV
thymidine kinase gene (BXLF-1) was performed as described by Brengel-Pesce
et al. (4) with omission of uracil DNA glycosylase. Dilutions of DNA extracted
from Namalwa cells, containing two integrated copies of EBV genomes per cell
(21), were used as the external standard. Samples were measured in duplicate.
Amplifications of the EBV genome were performed with the number of cycles
ranging from 25 to 38. The calibration curve allowed the establishment of the
following equation for the number of EBV genomes: y  3.320x  41.50, with
an R2 value of 0.99 and an error of 0.079. Genomic DNA was quantified by
amplification of the -globin gene. Standardization was performed with DNA
from the LightCycler control kit (Roche Molecular Diagnostic, Meylan, France).
The calibration curve allowed the establishment of the following equation: y 
3.312x  30.06, with an R2 value of 1 and an error of 0.0941.
Preparation of RNA, RT-PCR, and Southern blot hybridization. Frozen spec-
imens were pulverized, and total RNA was isolated from frozen tumor tissues,
using TRIzol reagent (Gibco-BRL, Gaithersburg, MD) according to the manu-
facturer’s instructions. After treatment of 10 g of extracted RNA with RQ1
RNase-free DNase (Promega Corp., Madison, WI), cDNA was synthesized from
1 g of treated RNA using Moloney murine leukemia virus reverse transcriptase
(Promega Corp., Madison, WI). PCR was carried out with the cDNA samples
obtained from 33 ng of total RNA in a final volume of 50 l, containing 2 l of
first-strand cDNA, 1 PCR buffer, 2.5 mM MgCl2, 200 nM concentrations of
each primer (Table 1), and 250 M deoxynucleoside triphosphates. Reactions
were incubated at 95°C for 5 min, and 3 U of Taq DNA polymerase was added
to each tube. Forty cycles of cDNA amplification were performed in a DNA
thermal cycler (Perkin-Elmer Corp., Foster City, CA) with the following condi-
tions: denaturing at 95°C for 30 s, hybridization at 58°C (55°C for LMP-1
amplification) for 1 min, and elongation at 72°C for 2 min, followed by a final
elongation at 72°C for 7 min. Ten microliters of each PCR product was analyzed
by electrophoresis in 2% agarose gel and transferred to nylon membranes by
Southern blotting (Hybond; Amersham Life Science Inc., Arlington Heights, IL).
The blots were prehybridized at 65°C for 2 h with 100 g/ml of denatured salmon
sperm DNA in 6 SSC (1 SSC is 0.15 M NaCl plus 0.015 M sodium citrate),
5% sodium dodecyl sulfate (SDS), and 5 Denhardt’s buffer. Hybridization was
performed with an LMP-1 or EBNA-1 cDNA that was labeled with [	-32P]dCTP
using the Klenow fragment of DNA polymerase I (106 cpm/ml). Following
overnight incubation, membranes were washed twice for 15 min with 2 SSC–
0.1% SDS at room temperature, twice with 2 SSC–0.1% SDS at 65°C for 15
min, and twice with 0.1 SSC–0.5% SDS at 65°C for 30 min. The blots were then
exposed to X-ray film for imaging.
Cell culture and infection. MDA-MB-231 cells (a cell line derived from pleural
effusions of a breast cancer patient.) (5) were grown in RPMI 1640 (Life Tech-
nologies, GIBCO BRL, Gaithersburg, Md.) supplemented with 10% fetal bovine
serum and antibiotics at 37°C in a 5% CO2 humidified atmosphere. The Akata
cell clone infected with recombinant EBV (rEBV) was maintained in RPMI 1640
containing 10% fetal bovine serum and G418 (700 mg/ml; Invitrogen, The Nether-
lands). MDA-MB-231 cells were infected by cocultivation with Akata cells pro-
ducing rEBV following induction by anti-human immunoglobulin G, as previ-
ously described (16). Infected clones were selected after cultivation with G418,
and four clones were studied: C1D12, C2G6, C3B4, and C4A3.
Evaluation of cell survival. Three thousand MDA-MB-231 cells attached in a
microplate well were subjected to paclitaxel (Sigma). After 3 days, the cell number
was estimated by means of the endogenous enzyme hexosaminidase (20).
MDR1 expression. Evaluation of the expression levels of MDR1 (normalized
to the housekeeping 2-microglobulin gene) was performed by real-time quan-
titative PCR using a LightCycler (Roche Diagnostics, France) as described
previously (24). 2-Microglobulin and MDR1 selected sets of primers and flu-
orescent probe (Eurogentec, Biosense, Italy) are the following: b2m forward,
5
CGC TCC GTG GCC TTA GC 3
; b2m reverse, 5
 GAG TAC GCT GGA
TAG CCT CCA 3
; b2m probe, 5
 6-carboxyfluorescein (FAM) TGC TCG CGC
TAC TCT CTC TTT CTG GC 3
 6-carboxytetramethylrhodamine (TAMRA);
MDR1 forward, 5
 TGA TGA CCC TAA AAA CAC CAC TG 3
; MDR1
reverse, 5
 GAA CCT ATA GCC CCT TTA ACT TGA 3
; MDR1 probe, 5

FAM AGC ATT GAC TAC CAG GCT CGC CAA 3
 TAMRA. Standards for
MDR1 and 2-microglobulin were prepared from total normal RNA, amplified
by RT-PCR, and cloned using a TOPO II TA cloning kit (Invitrogen, France)
following the manufacturer’s recommendations.
RESULTS
Viral load in breast cancer tissue specimens. Q-PCR assays
were performed on 95 whole samples of the breast cancer
biopsy tissues. In 51 cases, no copies of the EBV genome were
amplified or the number was below the threshold of detection.
Forty-four samples were considered positive for EBV, since 2
to 6,000 copies were detected in the assay. Table 2 shows the
number of copies of the EBV genome detected in each of the
44 EBV-positive tumor samples. The copy number per 1,000
total cells is determined assuming that one cell contains 6 pg of
DNA. The number of EBV genomes was very low; we mea-
sured in 9 samples less than 0.1 copy per 1,000 total cells, in 18
samples 0.1 to 0.8 copy per 1,000 total cells, and in 14 samples
1 to 19 copies per 1,000 cells. In two samples, an average of 700
copies was detected, corresponding to 303 and 338 copies in
1,000 total cells. In one sample, exhibiting the highest load, 883
copies per 1,000 cells were measured. In two NPC biopsy
specimens, 1.8 and 6 million copies of the EBV genome were
detected, corresponding to 27 and 25 copies per cell, respec-
tively (Table 2). The copy number of the EBV genome in
breast cancer biopsy specimens is thus very low compared to
the ones observed in NPC; however, the EBV genomes were
detected, and specimens were considered positive compared to
the results obtained in five pellets of peripheral blood lympho-
cytes from healthy donors, in which the level of EBV DNA was
below the threshold of detection.
TABLE 1. Oligonucleotide sequences
Target Primer Primer sequence (5
33
)
B95-8 genomic
coordinates
(nucleotides)
EBNA-1 E1AS TTGCAGCCAATGCAACTTGG 108197–108178
E1S AGAGAGTAGTCTCAGGGCAT 67545–67564
BamH1U UPUS GTTCCTCGGTGGCGGGCTTA 67378–67397
ExonUAS U172AS ATGCCCTGAGACTACTCTCT 67564–67545
LMP-1 LMP1S CTGAGGATGGAACACGACCT 169480–169461
LMP1AS AATGGAGGGAGAGTCAGTCA 168099–168108
BARF-1 BARF1S GGCTGTCACCGCTTTCTTGG 165560–165579
BARF1AS AGGTGTTGGCACTTCTGTGG 165762–165743
BamH1A BamAS CGTGGTGAAGCCTCTAACGC 165883–165902
BamAAS GGCAAGTGCGTTTATTGCGA 166180–166161
BZLF1 ZS TTACACCTGACCCATACCAG 103118–103099
ZAS1 ACATCTGCTTCAACAGGAGG 102284–102303
HPRT HPRTS TATGGACAGGACTGAACGTC
HPRTAS GTTGAGAGATCATCTCCACC
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Detection and quantification of the EBV genome in isolated
malignant epithelial cells of breast tumor biopsy specimens. In
order to evaluate the relevance of a low number of viral genomes
and to identify the EBV-infected cells within the breast cancer
biopsy specimens, we determined the EBV DNA load in isolated
cancer cell populations. Six breast cancers from Institut Gustave
Roussy were analyzed. Four of them were considered EBV pos-
itive, since 4, 11, 2, and 5 copies of the EBV genome were
detected in a Q-PCR assay in tumor numbers 240, 393, 200, and
275, respectively. Tumor cells were separated from stromal tissue
and normal breast cells by laser capture microdissection (LCM).
Figure 1A shows a representative target tissue sample before
laser dissection, and Fig. 1B shows the malignant epithelial cells
captured after LCM. DNA from two to four different areas con-
taining only carcinomatous epithelial cells was isolated, and the
viral load was quantified by Q-PCR. No EBV genomes were
detected in three different microdissections taken from two of the
six tumors (data not shown). The results obtained with the four
EBV-positive tumors are summarized in Table 3. In the micro-
dissected specimens, although the tumor cell population ap-
peared to be homogeneous, only one of four clusters of tumor
cells taken from tumor 240 contained EBV genomes (100 copies
in 1,000 cells). Similarly, in tumor 393, one of the two studied
regions was EBV positive (855 copies in 1,000 cells). All studied
regions of the other two tumors (200 and 275) were positive,
exhibiting viral loads from 15 to 465 and from 49 to 6,333 copies
in 1,000 cells, respectively, showing again a high heterogeneity in
viral load. The EBV genome was clearly detected in malignant
epithelial areas taken from the four EBV-positive biopsy speci-
mens, demonstrating that the virus is harbored by epithelial cells
and not accounted for by infiltrating lymphocytes.
We compared the average viral load detected in the whole
tumor specimen with that determined for different microdis-
sected clusters of tumor cells. As expected from the heteroge-
neity of viral distribution in the tumor cells, the viral load
determined within the entire tumor specimen is much lower
than that found within a virus-positive region. We determined
that in tumor 393, 0.02 copies of the EBV genome were found
per 1,000 total cells, although one microdissected region con-
tained 855 copies per 1,000 cells. This result shows that even if
a very low copy number of EBV genomes is detected within a
whole biopsy specimen, a high copy number can be present in
different parts of the tumor.
Detection of EBV transcripts in breast carcinoma biopsy
specimens. Tumors harboring the highest viral load were cho-
sen for investigation of EBV expression if a sufficient amount
of tissue was available. EBNA-1, BARF-1, and LMP-1 RNA
expression was studied in whole tumor specimens. We tested
for EBNA-1 transcripts by RT-PCR in RNAs from 21 EBV-
positive tumors using E1S and E1AS primers (Table 1) and
detected EBNA-1 RNA in 17 of the specimens. An amplified
band of the expected size (361 bp) hybridized with labeled
specific probe in each case. Typical examples are shown in
Fig. 2Ba. Tumors 13, 14, 17, 18, 19, and 21 were positive for
EBNA-1 cDNA, while 15 and 20 were negative. Amplification
of hypoxanthine-guanine phosphoribosyl transferase (HPRT)
cDNA was carried out in each case to control for the quality of
the cDNAs (36) (data not shown). These results show that an
EBV gene is expressed and detected in almost all of the EBV-
positive breast tumors.
In order to detect LMP-1 transcripts, we used primers
LMP1S and LMP1AS (Table 1 and Fig. 2Ab). Amplification
was performed with cDNA obtained from breast carcinoma
biopsy specimens. Three of fifteen samples were positive for
TABLE 2. Detection of the EBV genome by Q-PCR in biopsied
EBV-positive breast cancer tissues
Cased DNA(ng)a
Cell
equivalentsb
No. of EBV
genomesc
Copies of
EBV/1,000
cells
BK71 1,606 267,667 4 0.02
BK66 2,386 397,667 6 0.02
BK67 2,505 417,500 8 0.02
BK34 1,096 182,667 5 0.03
BK88 612 102,000 3 0.03
BK69 967 161,166 6 0.04
BK72 890 148,334 6 0.04
BK61 921 153,500 7 0.05
BK62 318 53,000 4 0.08
BK47 188 31,334 3 0.10
BK56 314 52,334 6 0.11
BK70 1,651 275,166 30 0.11
BK39 181 30,166 4 0.13
BK49 291 48,500 7 0.14
BK37 193 32,166 6 0.19
BK6 379 63,166 16 0.25
BK25 134 22,334 7 0.31
BK95 84 14,000 5 0.38
BK83 48 8,000 3 0.38
BK15 141 23,500 9 0.38
BK38 31 5,166 2 0.39
BK24 94 15,667 8 0.51
BK7 248 41,334 22 0.53
BK16 76 12,667 7 0.55
BK12 17 2,833 2 0.70
BK9 73 12,166 10 0.83
BK65 43 7,166 6 0.84
BK21 36 6,000 6 1
BK51 1,277 212,833 214 1
BK68 20 3,334 4 1.2
BK13 93 15,500 23 1.5
BK22 83 13,833 22 1.6
BK30 79 13,166 23 1.8
BK27 363 60,500 118 2
BK40 208 34,667 93 2.7
BK42 12 2,000 7 3.5
BK17 6 1,000 4 4
BK4 163 27,166 214 8
BK8 14 2,334 20 9
BK32 47 7,833 93 12
BK3 54 9,000 170 19
BK2 14 2,334 708 303
BK5 12 2,000 676 338
BK23 47 7,833 6,918 883
NPC1 1,315 219,166 6  106 27,376
NPC2 425 70,833 1.8  106 25,400
PBLKu15 970 161,667 0 0
PBLKu27 6,940 1.16  106 0 0
PBLhk35 17,350 2.9  106 0 0
PBLhk39 2,150 358,334 0 0
PBLiKa49 6,100 106 0 0
a Quantified by amplification of the ß-globin gene.
b Based on the assumption that one cell contains 6 pg of DNA and that there
are two copies of the globin gene per cell.
c Expressed as the mean of the results of two assays.
d BK corresponds to breast cancer biopsies, NPC to nasopharyngeal carci-
noma, and PBL to peripheral blood lymphocytes.
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LMP-1 cDNA amplification, as demonstrated by amplification
and specific hybridization of a 377-bp band (Fig. 2Bb).
Expression of the EBV BARF-1 gene was investigated by
RT-PCR in 14 different breast cancer biopsy specimens using
BARF1S and BARF1AS primers. Figure 2Bc shows that a
band of the expected size (202 bp) was amplified from cDNAs
of 8 of the 14 biopsy specimens. In order to be sure that the
bands obtained correspond to copies of cDNA and not to
DNA contamination, PCR of untranscribed regions was per-
formed with combinations of primers lying in the U and A
FIG. 1. Laser capture microdissection (LCM) of breast cancer tissue. Frozen tumor sections (10 m thick) stained with Mayer’s hematoxylin
and eosin Y were microdissected with the Arcturus PixCell II system to procure homogeneous cell populations. Panel A shows a section before
LCM. Panel B shows clusters of the malignant epithelial cells captured by LCM. These are representative sections from the total microdissections
summarized in Table 3.
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fragments, one primer upstream (UPUS) of the U172 exon
and one primer within the U172 exon (U172AS), and also with
the combination of one primer (BamAAS) downstream of the
BARF-1 sequence and one within the BARF-1 open reading
frame (BamAS). No band was obtained with these different
cDNA preparations, whereas bands of the expected sizes (185
bp and 317 bp, respectively) were detected after amplification
of DNA extracted from B95-8 cells, showing that no genomic
DNA was detectable in the cDNA preparations.
BZLF1 expression was assayed in two EBV-negative (986
and BK20) biopsy specimens, eight breast cancer biopsy spec-
imens which harbored the highest viral load for which enough
material was available (BK8, BK32, BK3, BK17, BK20, BK9,
BK40, and BK23, which contained 9, 12, 19, 4, 0.83, 2.7, and
883 EBV copies/1,000 cells, respectively) (Table 2), and 275
specimens that carried EBV in four of four clusters of tumor
cells isolated by LCM (Table 3). RT-PCR followed by South-
ern blotting was performed. In two tumors, BK3 and BK40,
BZLF1 expression was observed after different overexposure
of the blot. The pattern of expression is similar to what was
seen in NPC (7) and in breast tissues (15).
Paclitaxel resistance of in vitro EBV-infected MDA-MB-231
cells. The potential impact of EBV infection on breast carci-
noma cells was investigated. The sensitivity of MDA-MB-231
cells, infected or not infected by EBV, to an agent used in
chemotherapy was tested. The cells were subjected to treat-
ment of 3 days of different concentrations of paclitaxel (1, 10,
and 100 nM and 1 M). A representative experiment is shown
in Fig. 3. When cultured with 100 nM and 1 M paclitaxel,
40% and 23% of the noninfected cells survived. One of the
infected clones, C4A3, was highly resistant to paclitaxel, since
83% of the cells survived when cultured with 100 nM paclitaxel
and 79% survived in 1 M paclitaxel. Another clone, C2G6,
exhibited a resistance, since 60% and 40% of the cells survived
in 100 nM and 1 M paclitaxel, respectively. Several potential
mechanisms have been proposed to account for the resistance
to paclitaxel (for a review, see Orr et al. [29a]); these include
overexpression of the multidrug resistance gene (MDR1). We
explored the expression of the MRD1 gene in MDA-MB-231
cells as well as in the infected clones. The results are shown in
Fig. 4. The copy number of the MDR1 gene transcripts (nor-
malized to the housekeeping 2-microglobulin gene) was six-
fold higher in the C2G6 cell line than in the parental nonin-
fected MDA-MB-231 cell line. The levels of MDR1 expression
in the other infected clones were not dramatically increased
compared to the ones of the noninfected one. However, when
cultured in the presence of 100 nM paclitaxel, the level of
MDR1 transcripts was 10-fold higher in the C4A3 clone than
the level expressed without paclitaxel in the cultured medium.
In summary, in the presence of 100 nM paclitaxel, the level of
MDR1 transcripts normalized to 2-microglobulin expression
is 6- to 10-fold higher in C4A3 and C2G6 EBV-infected clones
than in the parental MDA-MB-231 noninfected clone. C4A3
and C2G6 are more resistant to paclitaxel than the two other
infected clones, C1D12 and C3B4. The resistance is correlated
with overexpression of the MDR1 gene. The mechanism con-
ferring paclitaxel resistance implicated in EBV-infected MDA-
MB-231 cells is currently under investigation.
DISCUSSION
Although a part of the literature showed negative results,
EBV has been detected in large subsets of infiltrating breast
cancer (3, 10, 19, 23). In this study, we detected EBV genomes
in various copy numbers in about half of the breast cancer
specimens analyzed. We accounted for this variability by mi-
crodissection of the specimens, which disclosed that the distri-
bution of EBV genomes in tumor cells was variable within each
tumor specimen even though morphologically the tumor cells
were indistinguishable. This observation may account for the
variable distribution of the EBNA-1 protein detected by im-
munohistochemistry (3). It is well known that different biolog-
ical markers (ER and/or PR, epidermal growth factor receptor,
and MMP-2) (35, 37, 38) are heterogeneously distributed
within breast cancer tissue. Moreover, Glockner et al. deter-
mined the amplification status of growth regulatory genes in
macroscopically and microscopically separate areas of individ-
ual breast cancers and showed marked intratumoral heteroge-
neity of c-myc and cyclinD1 (11). Intratumoral heterogeneity
mirrors subclonal diversity and might affect treatment re-
sponse. It appears that EBV genomes are also heterogeneously
distributed. It would be of interest to identify tissue markers
that may correlate with EBV genome content in breast cancer
cells that appear otherwise to be morphologically identical.
Our results point to heterogeneity in terms of EBV content in
populations of breast cancer cells that may be biologically
significant.
In different studies, evaluation of EBV in breast cancer has
disclosed very low viral loads (10, 27) which have even been
defined as EBV negative (31). Murray et al. (27) used 19
sections of paraffin-embedded breast cancer tissues. They mea-
sured 2, 12, and 5 samples, respectively, with less than 0.1, 0.1
to 0.9, and 1 to 7 copies of the EBV genome per 1,000 cells. We
had similar results but also detected two samples with 303 to
338 copies per 1,000 cells. Moreover, one sample with a load of
883 copies in 1,000 cells was identified among the 95 frozen
biopsy tissues. Similarly, one cluster of isolated tumor cells
TABLE 3. Samples in which the EBV genome was detected by
Q-PCR in whole tumors and microdissected tumor epithelial cells
Biopsy
no.
DNA
(ng)a
No. of cell
equivalentsb
No. of EBV
genomesc
Copies/
1,000
cells
240 0.03 5 0 0
0.035 5 0 0
0.05 8 0 0
0.08 13 13 100
393 0.015 2.5 0 0
0.015 2.5 2 855
200 4 667 10 15
1.5 250 20 80
3.9 650 54 83
0.26 43 20 465
275 0.07 12 76 6,333
1.2 200 28 140
1 167 12 72
1.6 267 13 49
a Quantified by amplification of the -globin gene.
b Based on the assumption that one cell contains 6 pg of DNA and that there
are two copies of the globin gene per cell.
c Expressed as the mean of the results of two assays.
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contained 6,333 copies of EBV DNA in 1,000 total cells. As
suggested by Huang et al. (15), lytic viral replication might
contribute to the detection of the EBV genome in breast can-
cer, since Zta protein has been immunostained in a small
number of cells from breast tumor. We detected BZLF1 tran-
scripts in two of the eight breast cancer biopsy specimens. More-
over, proteins expressed during the productive cycle might be
of importance for cell transformation: MMP9 is induced by
BZLF1 (43), BRL1 induces expression of FAS (22) and acti-
vates S-phase entry through E2F1 induction (33), and BZLF1
interacts with cell cycle progression and is able to form com-
plexes with p53 (45) and p65 (13), which play roles in the
control of apoptosis. Moreover, lytic gene expression protects
from cell death (17). However, it is also known that EBV
reactivation occurs in a few cells in NPC (7) in which infection
is predominantly latent, and such a phenomenon does not
preclude latent infection.
Since identification of infected cells within a tumor has pre-
FIG. 2. Detection of EBV transcripts by RT-PCR analysis in RNA preparations from breast cancer biopsies. The primer combinations used
are shown as arrows in the diagrams presented in panel A. For cDNA detection, the following primers were used: E1AS and E1S were used for
EBNA-1 (a), LMP1S and LMP1AS for LMP-1 (b), and BARF1S BARF1AS for BARF-1 (c), and ZS and ZAS1 for BZLF1 (e). For detection of
putative DNA contamination, BamAS and BamAAS (c) and U172AS and UPUS (d) were used as controls. Products obtained after RT-PCR are
shown in panel B after Southern blotting (Ba, Bb, and Bd) or on agarose gels stained with ethidium bromide (Bc). Amplification of EBNA-1 cDNA
is shown in panel Ba. MDA-MB-231 cells were used as the negative control, and EBV-infected MDA-MB-231 cells were used as the positive
controls for EBNA-1 cDNA amplification. LMP-1 cDNA amplification is shown in panel Bb. B95-8 and C3B4 (an EBV-infected MDA-MB-231
cell line) served as positive controls. BARF-1 cDNA amplification is shown in panel Bc, and BZLF1 amplification is shown in panel Bd. B95-8
cDNA served as a positive control for BARF-1 and BZLF1, and DNA from B85-8 served as a positive control for DNA amplification in BamH1A
and BamH1U.
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viously given conflicting results in the literature, evidence of an
association of EBV with breast cancer requires clarification.
Negative results could arise from several sources: lack of assay
sensitivity, storage of samples, use of fixed versus frozen tis-
sues, and heterogeneity of the cancer tissue. False-positive
results could arise from nonmonospecific antibody reagents or
from EBV-positive infiltrating B lymphocytes, the level of
which has been estimated to be 2 to 60 EBV-positive lympho-
cytes in 106 peripheral blood lymphocytes (25).
In order to test whether the detected EBV genomes were
harbored only by lymphocytes, we investigated the viral loads
in five pellets of peripheral blood lymphocytes from healthy
blood donors (Table 2). As these results were negative, we
concluded that most if not all of the EBV DNA detected in the
breast cancer biopsy specimens was of epithelial tumor cell
origin. We confirmed this conclusion by LCM analysis. Q-PCR
performed on epithelial tumor cells purified from EBV-posi-
tive tumors by microdissection shows that the isolated tumor
cells carry the viral genome and in much higher copy number
in several of the microdissected specimens. Six to seven micro-
dissections were also performed in the two biopsied specimens
of breast cancer tissue by Fina et al. (10). Their results also
showed heterogeneity of the viral load in samples containing
only epithelial cancer cells and that infiltrating lymphocytes
could not be the only source of the detected EBV.
In contrast, Murray et al. (27) failed to detect EBV genomes
in microdissected tissue. However, they did not sample differ-
ent areas of the same tumor but pooled all of the microdis-
sected cells from each specimen. Thus, dilution of EBV-posi-
tive cells by noninfected cells may have resulted. Moreover,
they analyzed fixed tissue, which resulted in lower sensitivity.
We show here quantification of EBV DNA in individual
microdissections of four different tumors. A large heterogene-
ity in distribution of viral genomes from one region to another
of the same tumor as well as among different tumors was
observed. Moreover, the numbers of EBV genomes in some of
the microdissected samples are not compatible with contami-
nation with B lymphocytes, since only 1 to 10 per 106 are EBV
positive. We also show that even when EBV is detected at a
“high” level within one given region, the whole tumor may
exhibit a very low viral load overall.
We have detected EBNA-1 staining with two EBNA-1 mono-
clonal antibodies (1H4, used for frozen sections, and 2B4, used on
paraffin sections) of breast cancer tumors (3), and we also de-
tected EBNA-1 transcripts in RNA taken from the same tumor.
Xue et al. (41) detected EBV transcripts in samples sorted for the
absence of lymphocytes. They detected EBNA-1 and BARF-1
RNA in three of six cases. We show here detection of EBNA-1,
BARF-1, and LMP-1, respectively, in 17 of 22, 8 of 14, and 3 of
15 cases. Expression of EBNA-1, BARF-1, and LMP-1 genes is of
importance. The EBNA-1 protein is required to replicate and
maintain the EBV genome in infected cells, LMP-1 is considered
to be the important EBV oncogene (18), and BARF-1 is able to
confer transforming properties in cells (29). Both LMP-1 and
BARF-1 are expressed in other carcinomas (32), in NPC and in
gastric cancers.
In conclusion, it is well known that morphologically indis-
tinguishable breast cancer cells in fact may comprise a heter-
ogeneous population of breast cancer cells Similarly, we have
now demonstrated that the distribution of EBV genomes in
seemingly identical cells is heterogeneous. Because EBV is
detected in only some breast cancer cells, it is unlikely to be a
primary etiologic agent.
Herrmann and Niedobitek (14) questioned the implication
of EBV in breast cancer, since the virus is detected in only a
subset of tumor cells. However, EBV might have a role at an
early step in carcinogenesis and then be lost after the devel-
opment of the tumor. Alternatively, infection with EBV at a
late state of tumor development might enhance oncogenic
properties, such as invasiveness, angiogenesis, and metastasis.
For example, it has been shown that LMP-1 induces matrix
metalloproteinase 9 (MMP9), cyclooxygenase-2 (COX2), and
vascular endothelial growth factor (VEGF) (26) and induces
and causes release of FGF-2 in human epithelial cells (39).
Moreover, a correlation between LMP-1 expression and the
presence of COX2 in NPC tissue was observed. These findings
FIG. 3. Comparative toxicity of paclitaxel to MDA-MB-231 cells
and to the different EBV-infected clones. Thirty thousand cells were
seeded in 100 l of culture medium in microtiter plates and incubated
for 72 h with various concentrations of paclitaxel. The viability was
assessed by means of the endogenous enzyme hexosaminidase. The
experiment was performed in triplicate.
FIG. 4. EBV infection up-regulates MDR1 expression in two dif-
ferent EBV-infected MDA-MB-231 cell clones. Quantitative real-time
RT-PCR analysis was performed on RNA extracted from cells exposed
during 72 h to 0.1 M paclitaxel; the transcript copy numbers relative
to the reference gene 2-microglobulin (b2m) were determined.
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raise the possibility that EBV might alter the phenotype of a
subpopulation of carcinomatous cells so that they become
more aggressive in behavior (40). Our results show that EBV
infection confers paclitaxel resistance to breast carcinoma cell
lines. This resistance might be a consequence of the higher
MDR1 expression that is observed in paclitaxel-resistant EBV-
infected cells (C4A3 and C2G6). Moreover, MDR is induced
by paclitaxel treatment in the C4A3 cells. The manner by which
the cells acquired high MDR1 gene expression has not yet
been defined. Overexpression of the MDR1 gene product may
be intrinsically expressed or acquired following chemothera-
peutic drug treatment. Different molecular mechanisms may
lead to MDR1 overproduction: increased mRNA stability, in-
creased translational initiation (42), hypomethylation of the
promoter (34), and changes in the spatial and temporal pattern
of histone modifications (1). How EBV affects those mecha-
nisms is yet to be uncovered. Overexpression of the MRD1
gene upon EBV infection might have an effect on therapeutic
treatment of the disease.
Whether EBV might have a role in breast cancer develop-
ment or progression now needs to be promptly investigated
with appropriate cell biologic tools.
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